SBIR/STTR Research Award

THIS PROPOSAL WILL ADDRESS THE COMMERCIAL POTENTIAL OF PERFORMING CELL SURFACE MARKER ANALYSIS UTILIZING MONOCLONAL ANTIBODIES TAGGED WITH A VARIETY OF HEAVY METAL COLLOIDS OF VARYING SIZE AND COLOR.

Award identifier 791356eceb5a59e8b39accc2a618570744ae0fde75b4200029ae12007d3baeecAwarding agency Department of Health and Human Services

Award amount

$46,425

Program and phase

SBIR · Phase I

Award year

1984

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Laboratory Sciences Institute
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THIS PROPOSAL WILL ADDRESS THE COMMERCIAL POTENTIAL OF PERFORMING CELL SURFACE MARKER ANALYSIS UTILIZING MONOCLONAL ANTIBODIES TAGGED WITH A VARIETY OF HEAVY METAL COLLOIDS OF VARYING SIZE AND COLOR. CURRENTLY CELL MARKER ANALYSIS, PROVEN TO BE CLINICALLY IMPORTANT IN THE DETECTION, DIAGNOSIS AND MONITORING OF HUMAN DISEASES, ARE PERFORMED EITHER MANUALLY VIA FLUORESCENT/LIGHT MICROSCOPY (IMPRECISE IDENTIFICATION AND STATISTICAL COUNTING ERRORS) OR BY FLOW CYTOMETRIC ANALYSIS (COSTLY CAPITAL EQUIPMENT OUTLAY). THE COMMERCIAL AVAILABILITY OF EASILY VISUALIZED, NONFLUORESCENT MONOCLONAL REAGENTS WILL PERMIT CLINICAL HOSPITAL LABORATORIES TO PERFORM CELL MARKER STUDIES ON ALREADY EXISTENT CAPITAL EQUIPMENT, IMAGE ANALYSIS SYSTEMS, WHICH PERFORM ROUTINE BLOOD CELL DIFFERENTIALS IN MANY LABS. THESE IMAGE ANALYSIS SYSTEMS ARE NOT CAPABLE OF FLUORESCENCE DETECTION WHICH NEGATES THEIR UTILIZATION WITH EXISTENT FLUORESCENT MONOCLONALS. ONE ASPECT OF THIS PROJECT WILL INVOLVE THE DEVELOPMENT OF SUCH NONFLUORESCENT HEAVY METAL COLLOID TAGS WHICH BECAUSE OF THEIR VARIABLE SIZE AND COLOR DIFFERENCES MAY BE USED IN COMBINATION RESULTING IN SAVINGS TO THE CUSTOMER. THESE WILL BE COUPLED TO A VARIETY OF COMMONLY USED AND SPECIALIZED MONOCLONAL REAGENTS AGAINST HUMAN LEUKOCYTES. THIS TECHNIQUE WILL PERMIT DIRECT VISUALIZATION OF THE CELLULAR ELEMENTS SPREAD IN A MONOLAYER OR THIN SECTION MANNER ON STANDARD MICROSCOPIC SLIDES. THIS WILL PERMIT INSTANT CYTOMORPHOLOGIC CORRELATION WITH THE CELL IN QUESTION. ALL NEW REAGENTS DEVELOPED WILL BE EVALUATED BY MANUAL AND FLOW CYTOMETRIC METHODOLOGIES IN A DOUBLE BIND TEST. ONCE DEVELOPED THE REAGENTS WILL BE MARKETED FOR CELL MARKER ANALYSIS USING DIRECT VISUAL ASSESSMENT (MANUAL AND/OR IMAGE ANALYSIS SYSTEMS) AS REAGENTS OR IN KIT FORM FOR USE IN THE ROUTINE CLINICAL LABORATORY. A SECOND ASPECT OF THIS PROPOSAL WILL ATTEMPT TO DEVELOP AND CHARACTERIZE SELECTED MURINE MONOCLONAL ANTIBODIES TO HUMAN TUMOR SPECIFIC ANTIGENS. ALL RESULTANT MONOCLONALS WILL BE CAREFULLY SCREENED AND CORRELATED WITH HISTOPATHOLOGIC INTERPRETATIONS. THE RESULTANT MONOCLONALS WILL BE TAGGED WITH THE NEW COLLOIDS AND WITH TRADITIONAL FLUORESCENT DYES FOR USE IN MANUAL, FLOW AND IMAGE CYTOMETRIC SYSTEMS. THESE STUDIES HAVE THE POTENTIAL TO IMPROVE THE LEVEL OF TESTING SENSITIVITY FOR CELL MARKER ANALYSIS BY MANUAL METHODOLOGIES THROUGH THE ELIMINATION OF PROBLEMS RELATED TO HUMAN (EYE) DETECTION OF FLUORESCENCE INTENSITY AS THE COLLOIDS ARE ASSESSED BY LIGHT TECHNIQUES, AND WILL AFFORD UTILIZATION OF ALREADY EXISTENT CLINICAL LAB EQUIPMENT.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.